Samuel T. Wilkinson, MD
Advertisement
Articles by Samuel T. Wilkinson, MD
Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.
What is the efficacy of ECT for the treatment of dementia?
Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.
Advertisement
Latest Updated Articles
The Effects of Multidose Ketamine Treatment on Cognitive Performance Over Time in Patients With TRDPublished: June 25th 2024 | Updated:
What Is the Deal With Esketamine?Published: April 6th 2020 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia
2
FDA Approves First At-Home Brain Stimulation Device for Treatment of Depression
3
Alive at the End of the World
4
Semaglutide Potentially Protective Against Nephrotoxicity Caused by Lithium
5
